This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Labcorp (LH) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Labcorp (LH) delivered earnings and revenue surprises of 1.47% and 0.44%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Conmed (CNMD) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 11.67% and 1.36%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for December 27th
by Zacks Equity Research
BIDU, XRAY and PLOW have been added to the Zacks Rank #5 (Strong Sell) List on December 27, 2024.
Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio Now
by Zacks Equity Research
XRAY continues to gain traction from a robust product portfolio. However, the suspension of Byte's business and macroeconomic factors, such as weakened global demand, persist.
New Strong Sell Stocks for December 5th
by Zacks Equity Research
AKBA, KOF and XRAY have been added to the Zacks Rank #5 (Strong Sell) List on December 5, 2024.
Dentsply (XRAY) International Revenue Performance Explored
by Zacks Equity Research
Evaluate Dentsply's (XRAY) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
XRAY Q3 Earnings & Revenues Beat Estimates, 2024 Guidance Revised
by Zacks Equity Research
DENTSPLY SIRONA's third-quarter results showcase strong top-line growth in the Essential Dental Solutions segment. However, the lowered outlook for fiscal 2024 is a cause of concern.
Dentsply (XRAY) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Dentsply (XRAY) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Dentsply International (XRAY) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Dentsply (XRAY) delivered earnings and revenue surprises of 4.17% and 0.89%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy, Sell or Hold DENTSPLY SIRONA Before Q3 Earnings?
by Zacks Equity Research
XRAY's third-quarter results are likely to reflect growth in the Wellspect Healthcare business and Orthodontic segment amid foreign exchange headwinds.
Analysts Estimate Dentsply International (XRAY) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Dentsply (XRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Conmed (CNMD) Surpasses Q3 Earnings Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 6.06% and 0.55%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Dentsply Sirona Shares Fall After Suspension of Byte Aligner Products
by Zacks Equity Research
XRAY suspends Byte Aligner sales, citing regulatory review with the FDA, shifting resources to bolster other business areas amid compliance efforts.
West Pharmaceutical Services (WST) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
West Pharmaceutical (WST) delivered earnings and revenue surprises of 22.52% and 5.07%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio Now
by Zacks Equity Research
XRAY continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
DENTSPLY SIRONA Stock May Gain on the Launch of Primescan 2
by Zacks Equity Research
XRAY introduces its new-generation intraoral scanner, Primescan 2, to provide effective and efficient care and comfort to patients.
Interpreting Dentsply (XRAY) International Revenue Trends
by Zacks Equity Research
Explore how Dentsply's (XRAY) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Dentsply (XRAY) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Dentsply (XRAY) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
DENTSPLY SIRONA (XRAY) Q2 Earnings Miss, Revenues Decline Y/Y
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) second-quarter 2024 results showcase a year-over-year decline in earnings as well as sales.
Dentsply International (XRAY) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Dentsply (XRAY) delivered earnings and revenue surprises of -2% and 1.16%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Will These 4 MedTech Stocks Beat Forecasts This Earnings Season?
by Indrajit Bandyopadhyay
Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how COR, XRAY, GEHC and GKOS are placed ahead of their earnings release.
What's in Store for DENTSPLY SIRONA (XRAY) in Q2 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) second-quarter results are likely to reflect growth in the Wellspect Healthcare business and Orthodontic segment amid foreign exchange headwinds.
Labcorp (LH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Labcorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Reasons to Retain DENTSPLY SIRONA (XRAY) in Your Portfolio Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
West Pharmaceutical Services (WST) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
West Pharmaceutical (WST) delivered earnings and revenue surprises of -14.12% and 4.83%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?